+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Genitourinary Drugs Market - Global Forecast 2026-2032- Product Image
Genitourinary Drugs Market - Global Forecast 2026-2032- Product Image
New

Genitourinary Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 182 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5454847
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The genitourinary drugs market is in a period of rapid change, shaped by evolving patient demographics, clinical advances, and increasingly complex access requirements. Senior decision-makers are seeking actionable insights to remain competitive while navigating shifting therapeutic, regulatory, and distribution landscapes.

Market Snapshot: Genitourinary Drugs Market Growth and Trends

The global genitourinary drugs market grew from USD 41.54 billion in 2025 to USD 43.33 billion in 2026. It is projected to expand at a CAGR of 4.32%, reaching USD 55.88 billion by 2032. This growth trajectory highlights strong demand across a spectrum of indications and regions, emphasizing the need for strategic alignment to capture emerging opportunities and manage risks in a dynamic therapeutic area.

Scope & Segmentation

This report delivers an in-depth analysis of the genitourinary therapeutics ecosystem, with a structural overview of market drivers, constraints, and opportunities. The following segmentation provides targeted guidance for clinical, commercial, and supply chain decision-makers:

  • Indications: Focus includes benign prostatic hyperplasia, erectile dysfunction, interstitial cystitis, overactive bladder, and urinary tract infection, each with unique clinical and market access dynamics.
  • Therapeutic Classes: Analysis spans five alpha reductase inhibitors, alpha blockers, anticholinergics, beta3 agonists, combination therapies, and PDE5 inhibitors, examining their distinct mechanisms and innovation opportunities.
  • Distribution Channels: Hospital, retail, and online pharmacies are evaluated alongside direct-to-patient and specialty pharmacy strategies.
  • End Users: Clinics (including general and urology clinics), homecare, and hospitals (subdivided into public, private, secondary care, specialty, and tertiary centers) are compared in terms of engagement and prescribing influence.
  • Product Attributes: Injectable, oral, and topical formulations are assessed, with additional review of capsule, tablet, and solution-based products, plus over-the-counter/prescription pathways.
  • Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific are analyzed, reflecting unique payer frameworks, regulatory structures, and infrastructure settings.

Key Takeaways for Senior Decision-Makers

  • Genitourinary therapies are diversifying with new delivery models and combination regimens, enabling differentiation beyond molecule class.
  • Alignment of clinical trial endpoints and payer priorities is increasingly vital to expedite reimbursement and secure formulary placements.
  • Digital health and telemedicine inform changing distribution patterns, supporting remote consultation, online fulfillment, and expanded adherence programs.
  • Operational agility is critical; companies with robust manufacturing and multi-sourced supply networks respond more effectively to regulatory or tariff disruptions.
  • Regional market access strategies must flex to local health system variation, cross-border trade realities, and infrastructure constraints.
  • Integrated evidence generation—including real-world data—strengthens payer negotiations and supports outcome-based value demonstration.

Tariff Impact on Supply Chains and Commercial Strategy

Tariff measures implemented in 2025 created new cost pressures along the supply chain, particularly impacting cross-border sourcing of active ingredients, excipients, and finished products. In response, manufacturers diversified suppliers, increased regional production, and adjusted inventory management strategies. Distributors and pharmacies faced higher procurement costs, with some shifting to alternative stocking methods or negotiating new channel partnerships. Tariffs also influenced R&D collaboration decisions and led to a re-emphasis on local alliances and manufacturing to reduce exposure to trade uncertainties. Greater supply chain resilience and localization are now significant strategic considerations for sustained market performance.

Methodology & Data Sources

Analysis in this report is underpinned by a mixed-methods research framework, incorporating primary interviews with clinicians, payers, and supply chain partners, thorough regulatory review, and triangulation with secondary clinical and policy literature. Real-world supply data and scenario testing are utilized to validate implications and ensure practical relevance. Limitations are addressed through targeted primary inquiry and expert feedback to minimize data lag and regional variation.

Why This Report Matters

  • Enables senior stakeholders to align commercial, clinical, and supply chain strategies with evolving payer and regulatory expectations.
  • Provides clear, actionable segmentation to guide resource allocation and market-entry planning tailored to local dynamics and emerging risks.
  • Equips leaders to anticipate structural drivers of change and capitalize on shifts in therapeutic delivery, digital engagement, and sourcing strategy for sustained market growth.

Conclusion

The genitourinary drugs market presents a complex landscape where integrated commercial, evidence, and operational strategies are essential. Stakeholders adopting coordinated approaches will be best positioned for enduring patient access and business performance.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Genitourinary Drugs Market, by Indication
8.1. Benign Prostatic Hyperplasia
8.2. Erectile Dysfunction
8.3. Interstitial Cystitis
8.4. Overactive Bladder
8.5. Urinary Tract Infection
9. Genitourinary Drugs Market, by Therapeutic Class
9.1. 5 Alpha Reductase Inhibitors
9.2. Alpha Blockers
9.3. Anticholinergics
9.4. Beta3 Agonists
9.5. Combination Therapies
9.6. Pde5 Inhibitors
10. Genitourinary Drugs Market, by Route Of Administration
10.1. Injectable
10.2. Oral
10.3. Topical
11. Genitourinary Drugs Market, by Formulation
11.1. Capsules
11.2. Injectable Solutions
11.3. Oral Solutions
11.4. Tablets
12. Genitourinary Drugs Market, by Sales Model
12.1. Over The Counter
12.1.1. In-Store
12.1.2. Online
12.2. Prescription
13. Genitourinary Drugs Market, by Distribution Channel
13.1. Hospital Pharmacies
13.1.1. Private Hospitals
13.1.2. Public Hospitals
13.2. Online Pharmacies
13.3. Retail Pharmacies
13.3.1. Chain Pharmacies
13.3.2. Independent Pharmacies
14. Genitourinary Drugs Market, by End User
14.1. Clinics
14.1.1. General Practice Clinics
14.1.2. Urology Clinics
14.2. Homecare
14.3. Hospitals
14.3.1. Secondary Care Centers
14.3.2. Specialty Clinics
14.3.3. Tertiary Care Centers
15. Genitourinary Drugs Market, by Region
15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific
16. Genitourinary Drugs Market, by Group
16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO
17. Genitourinary Drugs Market, by Country
17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea
18. United States Genitourinary Drugs Market
19. China Genitourinary Drugs Market
20. Competitive Landscape
20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. Abbott Laboratories
20.6. AbbVie Inc.
20.7. Amgen Inc.
20.8. Astellas Pharma Inc.
20.9. AstraZeneca plc
20.10. Aurobindo Pharma Limited
20.11. Bayer AG
20.12. Boehringer Ingelheim International GmbH
20.13. Bristol-Myers Squibb Company
20.14. Cipla Limited
20.15. Dr. Reddy’s Laboratories Limited
20.16. Eli Lilly and Company
20.17. Endo International plc
20.18. F. Hoffmann-La Roche AG
20.19. Ferring International Center S.A.
20.20. GlaxoSmithKline plc
20.21. Hikma Pharmaceuticals PLC
20.22. Johnson & Johnson Services, Inc.
20.23. Melinta Therapeutics Inc.
20.24. Merck & Co., Inc.
20.25. Novartis AG
20.26. Pfizer Inc.
20.27. Sanofi S.A.
20.28. Takeda Pharmaceutical Company Limited
20.29. Teva Pharmaceutical Industries Ltd.
20.30. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GENITOURINARY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GENITOURINARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INTERSTITIAL CYSTITIS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVERACTIVE BLADDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY 5 ALPHA REDUCTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BETA3 AGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BETA3 AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY BETA3 AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PDE5 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PDE5 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PDE5 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INJECTABLE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ORAL SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IN-STORE, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IN-STORE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY IN-STORE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GENERAL PRACTICE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY UROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SECONDARY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SECONDARY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 118. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SECONDARY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 120. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 121. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TERTIARY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 123. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TERTIARY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 124. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY TERTIARY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 129. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 131. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 132. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 133. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 134. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 135. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 136. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 137. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 138. AMERICAS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 143. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 144. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 145. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 146. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 148. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 149. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 151. NORTH AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 157. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 158. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 159. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 161. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 162. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 163. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 164. LATIN AMERICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 178. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 179. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 180. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 181. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 182. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 183. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 184. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 185. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 187. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 188. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 190. EUROPE GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 195. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 196. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 197. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 198. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 199. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 200. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 201. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 202. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 203. MIDDLE EAST GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 204. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 205. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 206. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 207. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 208. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 209. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 210. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 211. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 212. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 213. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 214. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 215. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 216. AFRICA GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 217. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 218. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 219. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 220. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 221. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 222. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 223. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 224. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 225. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 226. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 227. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 229. ASIA-PACIFIC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 230. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 231. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 233. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 234. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 235. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 236. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 237. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 238. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 239. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 240. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 241. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 243. ASEAN GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 244. GCC GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 245. GCC GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 246. GCC GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 247. GCC GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 248. GCC GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 249. GCC GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 250. GCC GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 251. GCC GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 252. GCC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 253. GCC GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 254. GCC GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 255. GCC GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 256. GCC GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 261. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 262. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 263. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 264. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 265. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 266. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 267. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 268. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 269. EUROPEAN UNION GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 270. BRICS GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 271. BRICS GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 272. BRICS GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 273. BRICS GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 274. BRICS GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 275. BRICS GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 276. BRICS GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 277. BRICS GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 278. BRICS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 279. BRICS GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 280. BRICS GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 281. BRICS GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 282. BRICS GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 283. G7 GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 284. G7 GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 285. G7 GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 286. G7 GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 287. G7 GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 288. G7 GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 289. G7 GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 290. G7 GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 291. G7 GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 292. G7 GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 293. G7 GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 294. G7 GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 295. G7 GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 296. NATO GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 297. NATO GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 298. NATO GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 299. NATO GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 300. NATO GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 301. NATO GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 302. NATO GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 303. NATO GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 304. NATO GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 305. NATO GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 306. NATO GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 307. NATO GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 308. NATO GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 309. GLOBAL GENITOURINARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 310. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 311. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 312. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 313. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 314. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 315. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 316. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 317. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 318. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 319. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
TABLE 320. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 321. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
TABLE 322. UNITED STATES GENITOURINARY DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
TABLE 323. CHINA GENITOURINARY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 324. CHINA GENITOURINARY DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 325. CHINA GENITOURINARY DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 326. CHINA GENITOURINARY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 327. CHINA GENITOURINARY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 328. CHINA GENITOURINARY DRUGS MARKET SIZE, BY SALES MODEL, 2018-2032 (USD MILLION)
TABLE 329. CHINA GENITOURINARY DRUGS MARKET SIZE, BY OVER THE COUNTER, 2018-2032 (USD MILLION)
TABLE 330. CHINA GENITOURINARY DRUGS M

Companies Mentioned

The key companies profiled in this Genitourinary Drugs market report include:
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche AG
  • Ferring International Center S.A.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Melinta Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages182
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 43.33 Billion
Forecasted Market Value ( USD ) by 2032 $ 55.88 Billion
Compound Annual Growth Rate4.3%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Genitourinary Drugs Market Report by Indication, Product, and Region 2025-2033 - Product Image

Genitourinary Drugs Market Report by Indication, Product, and Region 2025-2033

  • Report
  • 146 Pages
  • Global
From
Genitourinary Drugs Global Market Report 2025 - Product Image

Genitourinary Drugs Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Genitourinary Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Genitourinary Drugs - Global Strategic Business Report - Product Image

Genitourinary Drugs - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Genito-Urinary Drugs: Market Share, and Growth Analysis by Product Type (Antibiotics, Antispasmodics, Hormonal Therapies), Application, End User, Technology - Product Image

Genito-Urinary Drugs: Market Share, and Growth Analysis by Product Type (Antibiotics, Antispasmodics, Hormonal Therapies), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From

About the Genitourinary Drug Market

The Genitourinary Drug market is a subset of the pharmaceutical industry that focuses on drugs used to treat urological disorders. These drugs are used to treat a variety of conditions, including urinary tract infections, bladder control issues, kidney stones, and prostate enlargement. Genitourinary drugs are also used to treat erectile dysfunction, infertility, and other sexual health issues. These drugs are typically prescribed by urologists and other healthcare professionals. The Genitourinary Drug market is highly competitive, with many companies offering a variety of products. Some of the major players in the market include Pfizer, Merck, AstraZeneca, Sanofi, and Bayer. Other companies in the market include Allergan, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.